PSPouria Ahmadi Simab

Pouria Ahmadi Simab

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pouria Ahmadi Simab has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Rare Diagnosis of Dubin‐Johnson Syndrome During Pregnancy: A Case Report

    by Said Reza Modares Mousavi, Farab Pourhasan, Pouria Ahmadi Simab, Sepideh Beikmohammadi‐Gharehsaghghal, Daryoush Kaini‐Shamsabadi, Elaheh Karimzadeh‐Soureshjani

    Dubin‐Johnson Syndrome (DJS) is a rare inherited disorder characterized by isolated conjugated hyperbilirubinemia without significant liver damage. This syndrome is often diagnosed incidentally during routine blood tests, as it typically presents with minimal or no symptoms. The disease results from a genetic defect in the ABCC2 gene, which encodes the MRP2 protein responsible for transporting conjugated bilirubin out of hepatocytes. In individuals with DJS, the impaired function of MRP2 leads to the accumulation of conjugated bilirubin in the liver and bloodstream. This case report presents a 31‐year‐old female who, during pregnancy, developed icterus, which raised concerns about possible liver disease or viral hepatitis. However, further investigation revealed no significant liver dysfunction or risk factors for viral hepatitis. Laboratory tests showed elevated total and direct bilirubin levels, with normal liver enzymes, thus prompting further evaluation. Ultrasound imaging of the liver and biliary system revealed no signs of obstruction, and tests for viral hepatitis were negative. The patient's clinical history of icterus since childhood, combined with the laboratory findings, led to the suspicion of DJS. Notably, urine coproporphyrin analysis demonstrated a characteristic increase in coproporphyrin I, further supporting the diagnosis. Although DJS does not typically require treatment, the patient was provided with genetic counseling to inform her and her family about the condition and potential inheritance patterns. DJS presents a diagnostic challenge due to its subtle clinical features and the need to differentiate it from other causes of icterus, especially in pregnancy. This case highlights the importance of considering rare genetic disorders in the differential diagnosis of icterus and emphasizes the role of genetic testing in confirming the diagnosis. Early recognition of DJS allows for appropriate management and genetic counseling, ensuring that affected individuals can lead a normal life without major complications.

  • Open Access

    Artificial Intelligence Applications in Small Animal Medicine: The Current Status, Key Challenges, and Future Prospects with Special Emphasis on Blockchain Innovation

    by Fatemeh Shiri, Amin Shahinzadeh, Arya Heidari, Amirreza Safaie, Sina Ghanbari, Narges Safari, Amir Hossein Atazadeh, Pouria Ahmadi Simab

    Artificial intelligence (AI) and machine learning are rapidly transforming companion animal veterinary medicine. The present narrative review examined current applications, challenges, and future directions for AI in the care of dogs, cats, and other companion animals. The current study is based on a structured literature search across PubMed/MEDLINE, Scopus, and IEEE Xplore from January 2015 to April 2026, with clearly defined inclusion and exclusion criteria to ensure transparency and reproducibility. In diagnostic imaging, computer vision algorithms improve the speed and accuracy of interpreting radiographs, ultrasound, and dermatoscopic images, helping detect conditions such as hip dislocation, osteoarthritis, foreign bodies, skin lesions, and parasites. In digital pathology, AI aids in identifying abnormal cells from blood and histology slides, supporting diagnoses such as lymphoma and anemia. Wearable devices with AI algorithms continuously monitor physiological data, including activity, sleep, and early signs of pain. Natural language processing (NLP) extracts information from electronic health records to facilitate epidemiological studies. Despite this promise, several challenges remain. Technical hurdles include the need for large, high-quality annotated datasets, which are harder and more costly to obtain than in human medicine, and the high genetic diversity among dog and cat breeds, which makes it difficult to develop generalizable algorithms. Ethical and legal issues involve liability for diagnostic errors, data privacy, and algorithmic bias, requiring new regulatory frameworks. Practical barriers include high costs, integration into clinical workflows, and the need to train veterinarians to effectively use and critically evaluate AI outputs. Future progress depends on close collaboration among AI specialists, veterinarians, biologists, and industry. Priorities include developing cost-effective, user-friendly tools; creating internationally shared, standardized databases; and establishing ethical and professional guidelines. Blockchain may serve as a trust layer for recording and verifying data access events, rather than as a primary repository for large-scale medical data. Ultimately, AI is expected to act as a powerful assistant, not a replacement for veterinary expertise, enabling earlier diagnoses, personalized treatments, improved preventive care, and a better quality of life for companion animals and their owners.

  • Open Access

    A Rare Diagnosis of Caroli Syndrome in a Young Patient

    by Elaheh Karimzadeh‐Soureshjani, Farab Pourhasan, Pouria Ahmadi Simab, Sajjad Shojaei, Yasaman Mohammadian

    Caroli syndrome is a rare but serious congenital disorder associated with portal hypertension and polycystic kidney disease. Early diagnosis via imaging, particularly MRCP, is crucial to prevent life‐threatening complications such as cholangitis and biliary cirrhosis. Timely intervention and close monitoring can significantly improve patient outcomes.


  • Open Access

    A Rare Diagnosis of Dubin-Johnson Syndrome During Pregnancy: A Case Report

    by Said Reza Modares Mosavi, Farab Pourhasan, Pouria Ahmadi Simab, Sepideh Beik-Mohammadi Gharehsaghghal, Daryoush Kiani-Shamsabadi, Elaheh Karimzadeh-Soureshjani

  • Open Access

    Evaluation of Emerging Antimicrobials Resistance in Nosocomial Infections Caused by E. coli : The Comparison Results of Observed Cases and Compartmental Model

    by Babak Eshrati, Elaheh Karimzadeh-Soureshjani, Mahshid Nasehi, Leila Janani, Hamid Reza Baradaran, Saeid Bitaraf, Pouria Ahmadi Simab, Sara Mobarak, Sasan Ghorbani Kalkhajeh, Mohammad Kogani

    Background: In recent years, the global rise of antibiotic‐resistant Escherichia coli ( E. coli ) has become a significant threat to public health. This study aimed to identify and track outbreaks of antibiotic resistance, specifically among the antibiotics used to treat nosocomial E. coli infections. Materials and Methods: This hospital‐based study utilized data from a nosocomial infection surveillance system to investigate reported cases of antibiotic resistance. The study analyzed the results of 12,954 antibiogram tests conducted across 57 hospitals in 31 provinces of Iran. The data was divided into two periods: the first and second halves of 2017. Before developing a predictive model for resistant E. coli cases, the model’s validity was tested using the first half of the year’s data. The predicted cases were then compared to the actual observed cases in 2017, with a statistically significant difference indicating an outbreak. Findings: The study found that, in 2017, hospitals in Iran experienced an outbreak of E. coli resistant to ampicillin and ceftazidime. This resistance was more prevalent than expected, highlighting the emergence of these drugs as major contributors to nosocomial E. coli infections. Conclusion: This study demonstrated the utility of the compartmental model in forecasting outbreaks of antibiotic‐resistant E. coli . It provides a framework for investigating similar outbreaks in the future, using diverse data sources and methodologies.


  • Trichinella spiralis as a Potential Antitumor Agent: An Update

    by Soheil Sadr, Zahra Yousefsani, Pouria Ahmadi Simab, Had Jafari Rahbar Alizadeh, Arges Lotfalizadeh, Hassan Borji

    Due to the limited success of therapeutic strategies in treating tumors, a new practical potent approach is needed. This review aimed to investigate previous literature related to tumors and Trichinella spiralis (T. spiralis). In recent years, there has been growing interest in utilizing biological, viral, bacterial, yeast, and parasitic agents to cure cancers. According to several studies, some parasites could interferee with the tumors’ growth. There has been much discussion about some parasites’ applications to cure tumors in animals and humans. In studies, T. spiralis was found to have antitumor properties. The active proteins in T. spiralis, such as Caveolin-1, Heat shock proteins, and Ribosomal proteins, are thought to inhibit the growth of cancers, such as melanoma, myeloma, sarcoma, leukemia, stomach cancer, colon cancer, breast cancer, and lung cancer. In addition, these proteins are thought to induce apoptosis in specific neoplastic cells. Accordingly, antigens derived from parasites may be helpful in cancer immunotherapy. However, there are still many unanswered questions regarding Trichinella spiralis’ potential use as a biotherapy agent against cancer. Future studies should focus on the purification of parasite antigens and their use for wider-scale trials in animal models.


  • Open Access

    CRISPR-Cas9 as a Potential Cancer Therapy Agent: An Update

    by Soheil Sadr, Pouria Ahmadi Simab, Hassan Borji

    Cancer is the second leading cause of death globally and remains a major economic and social burden. Although our understanding of cancer at the molecular level continues to improve, more effort is needed to develop new therapeutic tools and approaches exploiting these advances. Due to its high efficiency and accuracy, the CRISPR-Cas9 genome editing technique has recently emerged as a cancer treatment strategy. Among its many applications, CRISPR-Cas9 has shown an unprecedented clinical potential to discover novel targets for cancer therapy and to dissect chemical-genetic interactions, providing insight into how tumors respond to drug treatment. Moreover, CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications. More importantly, the ability of CRISPR-Cas9 to accurately edit genes, not only in cell culture models and model organisms but also in humans, allows its use in therapeutic explorations this review, important considerations for the use of CRISPR/Cas9 in therapeutic properties are discussed, along with major challenges that will need to be addressed before clinical examinations for a complex and polygenic disease such as cancer. This review aimed to explore the potential of the CRISPR-Cas9 genome editing technique as a cancer treatment strategy. Specifically, we will discuss how CRISPR-Cas9 can be used to discover novel targets for cancer therapy and to dissect chemical-genetic interactions.


  • Open Access

    Phytosomes: A Promising Nanocarrier for Enhanced Delivery of Herbal Compounds in Cancer Therapy

    by Muhammad Saeed, Soheil Sadr, Arian Gharib, Narges Lotfalizadeh, Ashkan Hajjafari, Pouria Ahmadi Simab, Hassan Borji

    Cancer is a life-threatening disease that remains a global health problem, with millions of people diagnosed yearly. Despite significant progress in cancer treatment, conventional chemotherapy still faces several limitations, including poor solubility, low bioavailability, lack of selectivity, and severe side effects. Therefore, alternative therapeutic strategies are necessary to improve cancer therapy. This review aimed to provide an updated overview of phytosome complexes and their potential application in cancer therapy, including their formulation techniques, transportation mechanism through phytosome, and recent investigations on their efficacy in treating different types of cancers. In recent years, nanotechnology has emerged as a promising approach to cancer therapy, as it enables the delivery of therapeutic agents to the tumor site with higher selectivity and efficiency. Phytosomes are a nanotechnology-based drug delivery system conjugating plant extracts or phytoconstituents with phospholipids. This conjugation results in the formation of a complex with improved solubility, stability, and bioavailability. Phytosomes have been shown to enhance the pharmacokinetic profile of phytoactive compounds, allowing for better targeting and sustained release. Phytosomes of curcumin, resveratrol, and quercetin have demonstrated anticancer properties in various in vitro and in vivo models. Moreover, phytosomes have been used to deliver chemotherapeutic agents, such as paclitaxel, docetaxel, and camptothecin, with improved efficacy and reduced toxicity. Phytosome complexes offer a promising platform for cancer therapy due to their ability to enhance the bioavailability and efficacy of phytoactive compounds. Incorporating phytosomes in cancer therapy could lead to the development of more effective and less toxic treatments for different types of cancers. Further studies are needed to elucidate the mechanism of action of phytosomes and to optimize their formulation for clinical use.


  • Open Access

    Ameliorative Effect of Methanolic Extract of Broccoli (BMX) on Diclofenac Sodium (DIC)-Induced Oxidative Damage in Rat Kidney

    by Mahdeih Raeeszadeh, Pouria Ahmadi Simab

    Introduction: The objective of this study was to investigate the potential protective effect of the methanolic extract of broccoli against oxidative stress induced by diclofenac in rats. Non-steroidal anti-inflammatory drugs (NSAIDs) are known to cause nephrotoxicity, hence the need to explore the therapeutic potential of medicinal plants. Materials and methods: A total of 48 adult male Wister rats with a maximum age of 2-3 months with an average weight of 220 g were randomly divided into four equal groups (12 in each group The first group was control (C) and fed physiological saline without treatment, the second group was BC which treated with broccoli methanolic extract (BMX) at a dose of 500 mg/kg/Intraperitoneal injection, the third group was DC which treated with diclofenac sodium (DIC, 100 mg/kg, Intra-muscular injection), and the fourth group was BC plus DC which treated diclofenac sodium (100 mg/kg, Intra-muscular injection) and broccoli (500 mg/kg/ Intraperitoneal injection). After blood collection, serum was isolated, and urea, creatinine, interleukin-1, and TNF-α were measured in blood serum. In kidney tissue, malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) were measured. At the end of the study, the samples were taken for histopathological investigation. Results: The results of the present study indicated that diclofenac sodium causes severe kidney damage. The levels of creatinine and urea showed a significant increase in the DC group compared with the control and other treatment groups. The pro-inflammatory biomarkers in blood serum increased in the DC group and significantly decreased in the BC+DC group compared with control and other treatment groups. These changes were in line with the significant decrease of GPx and CAT enzyme levels in the DC group and its increase in the BC group. Malondialdehyde increased in the DC group and reached its lowest level in the BC group. Hyperemic changes, accumulation of inflammatory cells, and bleeding were indicators of diclofenac tissue poisoning reported in the kidney. Conclusion: The results of biochemical and histopathological showed that broccoli extract at the dosage of 500 mg/kg with strong antioxidant potential can drama a protective role against diclofenac damage in the kidney.